Robert Azelby Increases Stake in Tango Therapeutics

Robert Azelby, a key figure at Tango Therapeutics, Inc., recently increased his stake in the company. On June 19, 2026, he bought 35,910 shares. This move indicates his continued confidence in the biotech firm's potential.

Insider Buying and Selling at Tango Therapeutics, Inc.

On June 19, 2026, Robert Azelby acquired 35,910 shares of Tango Therapeutics, adding to his position in the company. This acquisition was not part of a pre-planned trading arrangement. Other insiders also made purchases earlier in June, with Mace Rothenberg buying 4,000 shares, Sung Lee acquiring 570 shares, Lesley Ann Calhoun purchasing 25,000 shares, and John Ketchum adding 25,000 shares to their holdings on June 5, 2026.

Other Institutional Activity in Tango Therapeutics

Various institutional investors have also been active in Tango Therapeutics. RTW Investments, LP increased its holdings by 11,809,392 shares, bringing its total to 13,300,620 shares valued at approximately $278.2 million, a significant 791.9% increase. Adage Capital Partners GP, L.L.C. added 2,201,561 shares, ending with 12,809,485 shares worth about $267.9 million, marking a 20.8% increase. On the other hand, TCG Crossover Management, LLC reduced its position by 2,231,023 shares, resulting in a total of 10,531,071 shares valued at $220.3 million, a 17.5% decrease. Farallon Capital Management LLC also decreased its stake by 3,964,000 shares, ending with 9,097,411 shares valued at $190.3 million, reflecting a 30.3% reduction.

Tango Therapeutics, Inc. Stock Up 21.6%

Shares of NasdaqGM:TNGX traded near $28.50 on Wednesday. Tango Therapeutics has a market cap of approximately $4.64 billion. The company is not currently profitable, with a forward P/E ratio of -18.19. The stock's 52-week range has seen lows of $4.60 and highs of $34.39. It has a 50-day moving average of $24.37 and a 200-day moving average of $14.34. Tango's current ratio is a robust 27.38, with a quick ratio of 26.51 and a debt-to-equity ratio of 8.38.

Analysts Set New Price Targets

Analysts have recently weighed in on Tango Therapeutics. On June 11, 2026, Canaccord Genuity maintained a buy rating with a price target of $42. Similarly, HC Wainwright & Co. reaffirmed a buy rating on June 9, with a target of $66. Leerink Partners, on June 8, maintained a buy rating, setting a target price of $69. The consensus among 11 analysts remains a strong buy, with a mean price target of $40.45.

About Tango Therapeutics

Tango Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in precision oncology. Founded in 2017, the company focuses on developing drugs for specific patient groups with unmet medical needs. Tango's lead products include PRMT5 inhibitors, such as TNG462 and TNG456, aimed at treating cancers like pancreatic, lung, and glioblastoma. The firm employs 137 people and is led by CEO Dr. Malte Peters.

Bottom Line

Robert Azelby's recent purchase of Tango Therapeutics shares suggests his confidence in the company's future prospects. Investors and analysts are closely watching the stock, given its role in the precision oncology sector. While insider transactions provide insights, remember that these reports are backward-looking and may not reflect current positions.